Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract ...
Current approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution to this challenge, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results